Comparison of vitamin K and non-vitamin K oral anticoagulants and the bleeding frequency in the emergency department.
Direct oral anticoagulants
Emergency department
Safety
Warfarin
Journal
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension
ISSN: 1179-1985
Titre abrégé: High Blood Press Cardiovasc Prev
Pays: New Zealand
ID NLM: 9421087
Informations de publication
Date de publication:
08 Jan 2024
08 Jan 2024
Historique:
received:
12
08
2023
accepted:
27
11
2023
medline:
8
1
2024
pubmed:
8
1
2024
entrez:
8
1
2024
Statut:
aheadofprint
Résumé
Safety studies of anticoagulant therapy have so far been conducted on many subjects in controlled conditions (i.e., clinically monitored) and demonstrated the noninferiority of new ones over old anticoagulant drugs. Data on the propositions for the presence of symptoms and signs of bleeding among various anticoagulants in the emergency department indicate that these data do not match the data published so far. The aim of the study was to investigate the differences in the frequency of bleeding and bleeding-related symptoms as a reason for emergency department attendance in patients on anticoagulant therapy. The study included patients from the emergency department of University Hospital for one year, who were on anticoagulant therapy and who met the inclusion criteria. Out of a total of 595 patients, 409 were on warfarin (68.74%), and the rest were taking direct oral anticoagulants (DOAC): dabigatran 71 (11.93%), rivaroxaban 66 (11.09%) and apixaban 49 (8.23%). Out of 409 patients taking warfarin, 34.4% were adequately anticoagulated with the frequency of bleeding 13.7%, while in 57.2% of patients, PT INR was higher than the reference values with the frequency of bleeding 15.0%. A comparison between all DOAC groups and adequately anticoagulated warfarin patients in the frequency of bleeding and bleeding-related symptoms as a reason for emergency attendance yielded a difference that was marginally statistically significant (Pearson Chi-Square = 7.554, p = 0.052). Monitoring the frequency of bleeding and bleeding-related symptoms in patients on oral anticoagulant therapy as a reason for emergency department attendance may be a new safety and efficacy factor in real-life patient scenarios.
Identifiants
pubmed: 38190093
doi: 10.1007/s40292-023-00616-y
pii: 10.1007/s40292-023-00616-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Italian Society of Hypertension.
Références
Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation. 2015;132:194–204. https://doi.org/10.1161/CIRCULATIONAHA.114.013267 .
doi: 10.1161/CIRCULATIONAHA.114.013267
pubmed: 25995317
pmcid: 4765082
Grymonprez M, Simoens C, Steurbaut S, De Backer TKL, Lahousse L. Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018: a systematic review and meta-analysis. Europace. 2022;24:887–98. https://doi.org/10.1093/europace/euab303 .
doi: 10.1093/europace/euab303
Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2Suppl):e44S–e88S. https://doi.org/10.1378/chest.11-2292
Pirmohamed M. Warfarin: almost 60 years and still causing problems. Br J Clin Pharmacol. 2006;62:509–11. https://doi.org/10.1111/j.1365-2125.2006.02806.x .
doi: 10.1111/j.1365-2125.2006.02806.x
pubmed: 17061959
pmcid: 1885167
Sikorska J, Uprichard J. Direct oral anticoagulants: a quick guide. Eur Cardiol Rev. 2017;12:40–5. https://doi.org/10.15420/ecr.2017:11:2 .
doi: 10.15420/ecr.2017:11:2
Roca B, Roca M. The new oral anticoagulants: reasonable alternatives to warfarin. Cleve Clin J Med. 2015;82:847–54. https://doi.org/10.3949/ccjm.82a.14052 .
doi: 10.3949/ccjm.82a.14052
Kermer P, Eschenfelder CC, Diener HC, Grond M, Abdalla Y, Althaus K, Berrouschot J, Cangür H, Daffertshofer M, Edelbusch S, Gröschel K, Haase CG, Harloff A, Held V, Kauert A, Kraft P, Lenz A, Müllges W, Obermann M, Partowi S, Purrucker J, Ringleb PA, Röther J, Rossi R, Schäfer N, Schneider A, Schuppner R, Seitz RJ, Szabo K, Wruck R. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—a national case collection. Int J Stroke. 2017;12:383–91. https://doi.org/10.1177/1747493019895654 .
doi: 10.1177/1747493019895654
pubmed: 28494694
Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1–16. https://doi.org/10.1007/s40262-013-0100-7 .
doi: 10.1007/s40262-013-0100-7
pubmed: 23999929
Belmar Vega L, de Francisco ÁLM, da Silva JB, Galván Espinoza L, Fernández FG. New oral anticoagulants in patients with chronic kidney disease. Nefrologia. 2017;37:244–52. https://doi.org/10.1016/j.nefro.2016.08.006 .
doi: 10.1016/j.nefro.2016.08.006
pubmed: 27939514
Byol W, Garonzik S, Boyd RA, Frost CE. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet. 2019;58:1265–79. https://doi.org/10.1007/s40262-019-00775-z
Coleman CI, Kreutz R, Sood N, Bunz TJ, Meinecke AK, Eriksson D, Baker WL. Rivaroxaban’s impact on renal decline in patients with nonvalvular atrial fibrillation: a US MarketScan Claims Database Analysis. Clin Appl Thromb Hemost. 2019;25:1076029619868535. https://doi.org/10.1177/1076029619868535 .
doi: 10.1177/1076029619868535
pubmed: 31392894
pmcid: 6829639
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet. 2014;383:955–62. https://doi.org/10.1016/S0140-6736(13)62343-0 .
doi: 10.1016/S0140-6736(13)62343-0
pubmed: 24315724
Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41:3–14. https://doi.org/10.1007/s11239-015-1311-6 .
doi: 10.1007/s11239-015-1311-6
pubmed: 26780736
pmcid: 4715842
Scharrer S, Primas C, Eichinge S, Tonko S, Kutschera M, Koch R, Blesl A, Reinisch W, Mayer A, Haas T, Austrian IBD Study Group. Inflammatory bowel disease and risk of major bleeding during anticoagulation for venous thromboembolism. Inflamm Bowel Dis. 2021;27:1773–83. https://doi.org/10.1093/ibd/izaa337
Levey AS, Stevens LA. Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010;55:622–7. https://doi.org/10.1053/j.ajkd.2010.02.337 .
doi: 10.1053/j.ajkd.2010.02.337
pmcid: 2846308
Prkačin I, Nesek Adam V, Cavrić G, Svaguša T, Kovačić M, Kovačević I. Direct oral anticoagulant therapy and drug interactions in patients with atrial fibrillation. Signa Vitae. 2017;13:68–70. https://doi.org/10.22514/SV131.032017.11 .
doi: 10.22514/SV131.032017.11
Shin J, Secora A, Alexander G, Inker L, Coresh J, Chang A, Grams ME. Risks and benefits of direct oral anticoagulants across the spectrum of GFR among incident and prevalent patients with atrial fibrillation. Clin J Am Soc Nephrol. 2018;13:1144–52. https://doi.org/10.2215/CJN.13811217 .
doi: 10.2215/CJN.13811217
pubmed: 30002224
pmcid: 6086708
Lip GYH, Al-Khatib SM, Cosi FG, Banerjee A, Savelieva I, Ruskin J, Blendea D, Nattel S, De Bono J, Conroy JM, Hess PL, Guasch E, Halperin JL, Kirchhof P, Cosio MDG, Camm AJ. Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? J Am Heart Assoc. 2014;3: e001179. https://doi.org/10.1161/JAHA.114.001179 .
doi: 10.1161/JAHA.114.001179
pubmed: 25164944
pmcid: 4310414
Graham DJ, Baro E, Zhang R, Liao J, Wernecke M, Reichman ME, Hu M, Illoh O, Wei Y, Goulding MR, Chillarige Y, Southworth MR, MaCurdy TE, Kelman JA. Comparative stroke, bleeding, and mortality risks in older medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019;132:596–604. https://doi.org/10.1016/j.amjmed.2018.12.023 .
doi: 10.1016/j.amjmed.2018.12.023
pubmed: 30639551
Rutherford OW, Jonasson C, Ghanima W, Söderdahl F, Halvorsen S. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2020;6:75–85. https://doi.org/10.1093/ehjcvp/pvz086 .
doi: 10.1093/ehjcvp/pvz086
pubmed: 31942972
pmcid: 7073510
Steinberg B, Shrader P, Thomas L, Ansell J, Fonarow G, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J, Singer DE, Peterson ED, Piccini JP, ORBIT-AF Investigators. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes. The ORBIT-AF II Registry. J Am Coll Cardiol. 2016;68:2597–604. https://doi.org/10.1016/j.jacc.2016.09.966 .
Gu ZC, Wei A-H, Zhang C, Wang X-H, Zhang L, Shen L, Li Z, Pan MM, Liu X-Y, Pu J, Lin H-W. Risk of major gastrointestinal bleeding with new vs conventional oral anticoagulants: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020;18:792–9. https://doi.org/10.1016/j.cgh.2019.05.056 .
doi: 10.1016/j.cgh.2019.05.056
pubmed: 31195162
Jukic I, Bingulac-Popovic J, Dogic V, Babic I, Culej J, Tomicic M, Vuk T, Sarlija D, Balija M. ABO blood groups and genetic risk factors for thrombosis in Croatian population. Croat Med J. 2009;50:550–8. https://doi.org/10.3325/cmj.2009.50.550 .
doi: 10.3325/cmj.2009.50.550
pmcid: 2802088
Jobski K, Hoffmann F, Herget-Rosenthal S, Dörks M. Drug interactions with oral anticoagulants in German nursing home residents: comparison between vitamin K antagonists and non-vitamin K antagonist oral anticoagulants based on two nested case-control studies. Clin Res Cardiol. 2020;109:465–75. https://doi.org/10.1007/s00392-019-01526-7 .
doi: 10.1007/s00392-019-01526-7
pubmed: 31286199
Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Hausler GK, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H, ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330–93 https://doi.org/10.1093/eurheartj/ehy136
Cerdá M, Cerezo-Manchado JJ, Johansson E, Martínez F, Fernández M, Varela A, Rodríguez S, Bosch F, Santamaría A. Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population. J Comp Eff Res. 2019;8:165–78. https://doi.org/10.2217/cer-2018-0134 .
doi: 10.2217/cer-2018-0134
pubmed: 30654626
Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Med. 2015;13:74. https://doi.org/10.1186/s12916-015-0322-7 .
doi: 10.1186/s12916-015-0322-7
pubmed: 25889849
pmcid: 4417329
Kereš T, Jukić I, Svaguša T, Prkačin I, Bingulac-Popović J, Vinković M, Hećimović A, Živković M, Parašilovac N. A1B and BB blood group genotypes are risk factors for pulmonary embolism. Wiener Klin Wochenschrift. 2021;133:1179–85. https://doi.org/10.1007/s00508-021-01882-3 .
doi: 10.1007/s00508-021-01882-3